Ocular Therapeutix is a biopharmaceutical company. Co. commercializes two products in the U.S.: DEXTENZA®, an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain; and ReSure® Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. Co.'s earlier-stage assets include: OTX-TKI, an axitinib intravitreal implant administered by fine-gauge needle for the treatment of wet age-related macular degeneration; OTX-CSI, a cyclosporine intracanalicular insert for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert for the treatment of the signs and symptoms of dry eye disease. The OCUL stock yearly return is shown above.
The yearly return on the OCUL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OCUL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|